Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Net Income (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Net Income for 16 consecutive years, with -$8.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income fell 282.26% to -$8.3 million in Q4 2025 year-over-year; TTM through Nov 2025 was -$6.9 million, a 8056.93% decrease, with the full-year FY2025 number at -$6.9 million, down 8056.93% from a year prior.
  • Net Income was -$8.3 million for Q4 2025 at Cryo Cell International, down from $749408.0 in the prior quarter.
  • In the past five years, Net Income ranged from a high of $1.2 million in Q2 2021 to a low of -$16.9 million in Q4 2023.
  • A 5-year average of -$858779.9 and a median of $645254.5 in 2022 define the central range for Net Income.
  • Peak YoY movement for Net Income: surged 231.49% in 2022, then plummeted 2111.63% in 2023.
  • Cryo Cell International's Net Income stood at -$637192.0 in 2021, then soared by 231.49% to $837822.0 in 2022, then tumbled by 2111.63% to -$16.9 million in 2023, then surged by 87.09% to -$2.2 million in 2024, then plummeted by 282.26% to -$8.3 million in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Net Income are -$8.3 million (Q4 2025), $749408.0 (Q3 2025), and $355785.0 (Q2 2025).